Method for sterilising a platelet lysate
AssigneeMaco Pharma
InventorsBruno Delorme, Sabrina Viau, Francis Goudaliez
Life of this patent
Estimating the term…
Abstract
A method for sterilising a platelet lysate in the liquid state comprising at least the endogenous growth factors TGF-beta 1, EGF, PDGF-AB, IGF-1, VEGF and bFGF. The method comprising freezing the liquid platelet lysate in order to obtain a frozen platelet lysate, and irradiating the frozen platelet lysate with ionising radiation in order to obtain a sterilised platelet lysate, the irradiation being adapted so as to preserve at least 80% of the concentration of at least one of the endogenous growth factors chosen from the group consisting of TGF-beta 1, EGF, PDGF-AB, IGF-1 and VEGF.
Claims7
A method for sterilizing a platelet lysate comprising:
- a. providing a liquid platelet lysate;
- b. freezing said liquid platelet lysate in order to obtain a frozen platelet lysate;
- c. irradiating said frozen platelet lysate in a non freeze-dried state with gamma radiation at an absorbed dose within the range from 35-60kGy to obtain a sterilized platelet lysate, said irradiation being adapted so as to preserve at least 80% of the concentration of at least one of the endogenous growth factors chosen from the group consisting of TGF-beta1, EGF, PDGF-AB, IGF-1, and VEGF.
A method for sterilizing a platelet lysate comprising:
- a. subjecting a platelet suspension to at least one freezing/thawing cycle so as to obtain a platelet lysate composition;
- b. separating said platelet lysate composition into a clear platelet lysate fraction and a cellular debris fraction;
- and
- c. isolating said platelet lysate fraction in the liquid step to create a liquid platelet lysate;
- d. freezing said liquid platelet lysate in order to obtain a frozen platelet lysate;
- e. irradiating said frozen platelet lysate in a non freeze-dried state with gamma radiation at an absorbed dose within the range from 35-60kGy to obtain a sterilized platelet lysate, said irradiation being adapted so as to preserve at least 80% of the concentration of at least one of the endogenous growth factors chosen from the group consisting of TGF-beta1, EGF, PDGF-AB, IGF-1, and VEGF.
Dependencies are inferred from the claim text.